Introduction
Anticoagulant therapy with vitamin K antagonists (VKA) is an effective treatment for both primary and secondary prevention of venous and arterial thrombosis. 1 Vitamin K antagonists have several serious disadvantages, like a narrow therapeutic window, large intra-and interpersonal variability in required dose and interactions with other drugs and diet. Despite intensive monitoring the time in therapeutic range (TTR) usually lies between 50 and 60%. [2] [3] [4] Improving stability of anticoagulation therapy with VKA (i.e. maintaining the INR in the therapeutic range) would reduce the risk of both hemorrhage and thrombosis by decreasing time above and below the therapeutic range, respectively.
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In recent years it has become clear that diet, and especially the intake of vitamin K 1 , plays an important role as a cause of the variability of the INR. [6] [7] [8] [9] The amount of dietary vitamin K 1 intake correlates with warfarin sensitivity, the actual INR level and the variability of the INR. [6] [7] [8] Furthermore, patients with a low intake of dietary vitamin K 1 were at higher risk for unstable anticoagulant control than those with normal intake. 8, 9 This led to the hypothesis that increasing the vitamin K 1 intake by supplementation would improve the stability of the INR control. Several scientific reports indeed showed an improvement of anticoagulant control by vitamin K 1 supplementation, both in healthy volunteers 10 , and in patients on anticoagulant therapy [11] [12] [13] without the necessity of a large increase of VKA dose needed to maintain a therapeutic INR. 14 Sconce et al investigated whether supplementation of 150 µg vitamin K 1 in a group of 70 patients with a history of instability of the INR would increase stability. In this study an improvement of the standard deviation of the mean INR by 0.24 in patients using vitamin K 1 in comparison to an improvement by 0.11 in the patients using placebo was seen. Also, a 13% improvement in TTR in favor of the vitamin 5 K 1 group was observed. 11 Rombouts et al performed a study in 200 patients who were already on anticoagulant treatment for at least one year. These patients were assigned to either 100 µg vitamin K 1 or a placebo. A difference of 3.6% TTR (95%CI: -0.8% -8.0%) was seen in favor of the vitamin K 1 group. 12 Several questions remain in this regard. Firstly, it is unclear whether all patients benefit from vitamin K 1 supplementation or only a subgroup such as unstable patients. Secondly, the most effective dose of vitamin K 1 was unknown because different dosages were used in the previous studies. Sconce et al used 150
µg and Rombouts et al used 100 µg. 11, 12 Thirdly, the type of vitamin K antagonist that is used might influence the effect of vitamin K 1 supplementation on the achieved stability, for longer acting VKA result in a more stable control per se. [15] [16] [17] [18] [19] Finally, supplementation with vitamin K 1 would only be useful in the clinic when the frequency of clinical endpoints such as the number of hemorrhages or thrombotic events would be reduced.
We planned a large study to investigate the effect of vitamin K 1 supplementation on stability and clinical endpoints. Before starting this large study with clinical endpoints we set up a dose-finding study to investigate the effect on stability of 100, 150 and 200 µg vitamin K 1 in comparison to placebo. The results of this dose finding study are presented here.
Design and methods

Study design
We set up a double blind, randomized, placebo controlled clinical trial. Four hundred patients starting with oral anticoagulant therapy with vitamin K antagonists were to be randomized into four equal groups, receiving either a placebo or 100 µg, 150 µg or 200 µg vitamin K 1 once daily next to their vitamin K antagonists. Patients were treated with either adjusted-dose phenprocoumon or acenocoumarol. The study medication was used for at least six months and was stopped: 1) when the anticoagulant therapy ended, or 2) when a patient had participated for a period of twelve months or, 3) when the study ended, which was six months after the last patient was included. Patients who continued vitamin K antagonists after the study ended were monitored at weekly intervals during at least four weeks to adjust for possible instability as a result from stopping the vitamin K 1 .
The study started at the Leiden anticoagulation clinic and was subsequently extended to the anticoagulation clinic Medial. Permission for this study was received from the local Medical Ethics Committee at the Leiden University Medical Center. Written informed consent was obtained from all patients willing to participate in the study. The study was registered in the ISRCTN-register under number ISRCTN37109430.
Participants
Participants were recruited from the Leiden anticoagulation clinic and the anticoagulation clinic Medial (region Haarlem / Hoofddorp). All patients between 18 and 85 years old and starting with low intensity oral anticoagulant therapy for at least 6 months were eligible. Exclusion criteria were: dialysis (both hemodialysis and peritoneal dialysis); pregnancy or current pregnancy wish; a life expectancy of less than six months due to any known condition; an expected interruption of anticoagulant therapy for more than one week and patients enrolling in the self-management program.
We argued that a 10% improvement in TTR would be clinically relevant and achievable. The standard deviation of time in therapeutic range was estimated at 23%. With a power of 80% and a significance level of 5% we calculated that 84 patients were needed in each group. Allowing a loss of 15% of patients in each group we included a total of 400 patients over 4 groups.
Procedures
Patients were treated according to the standard protocols of both anticoagulation clinics with either acenocoumarol or phenprocoumon, which are both registered and used in the Netherlands, to the referring physician's discretion. The anticoagulation clinics use integrated information databases and dosage algorithms, with routine recording of the dosages of vitamin K antagonists, along with relevant clinical information such as complications (both thromboembolic and hemorrhagic), hospital admissions, surgery and co-medication. After the treatment period ended the required data were extracted from these databases and analyzed. No specific dietary recommendations were given.
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The study capsules, placebo and vitamin K 1 , were manufactured by Numard B.V.
(Lelystad, the Netherlands). The vitamin K 1 capsules were made from 5% dry vitamin K 1 (Acatris, Londerzeel, Belgium) in three different dosages: 100 µg, 150 µg and 200 µg.
Data analysis
The main objective of the study was to investigate the dose dependent improvement of the One secondary endpoint was the chance of reaching stability, expressed as the odds ratio (OR) of reaching a high TTR in the vitamin K 1 group compared to the placebo group.
Another secondary endpoint was the number of complications, both thromboembolic and hemorrhagic. Major hemorrhage was defined according to Schulman et al 21 According to this classification, bleeding is defined as major hemorrhage if:
1. the hemorrhage is fatal, or, 2. the hemorrhage is symptomatic in a critical area or organ (like intracranial bleeding or intramuscular bleeding with compartment syndrome), or,
Results
Inclusion of patients started June 1 st 2008 and was completed July 1 st 2009. Figure 1 shows a flow chart of the patients during the study.
Out of 1890 eligible patients receiving an invitation to participate 400 were randomized in the four groups. Data from 369 patients was analyzed. The number of patients, follow-up time of each patient group and the patient characteristics are shown in Table 1 . The 150 µ g vitamin K 1 group enclosed more patients using phenprocoumon and more patients from the Leiden anticoagulation clinic. The 150 µ g and 200 µ g vitamin K 1
groups included more patients treated for atrial fibrillation and less other treatment indications than the other two groups.
The primary study outcome, weighted time in therapeutic range is presented in Tables 2A-2C . The unadjusted differences in weighted TTR between the placebo and the treatment groups were 2.2% (95%CI: -3.3% -7.7%), 3.9% (95%CI: -3.2% -11.0%) and 0.3% (95%CI: -5.3% -5.9%) for the 100, 150 and 200 µg vitamin K 1 groups respectively.
Adjustment for age, sex, vitamin K antagonist used, anticoagulation clinic and the use of interacting drugs resulted in a difference of 2.1% (95%CI: -3.2% -7.4%), 2.7% (95%CI: -2.3% -7.6%) and 0.9% (-4.5% -6.3%) for the 100, 150 and 200 µ g vitamin K 1 groups, respectively, all in reference to the placebo group. The unweighted adjusted differences are 3.3% (95%CI: -1.4% -7.9%) for the vitamin K 1 100 µg group, 4.5% (95%CI: 0.1% -9.0%) for the 150 µg group and 4.2% (95%CI: -0.5% -8.8%) for the 200 µg group, again all in reference to the placebo group. 3) ).
After the study ended 227 patients continued treatment with vitamin K antagonists (59 patients in the placebo group, 51 in the 100 µ g vitamin K 1 group, 60 in the 150 µg In the 200 µg group one intra-ocular hemorrhage was reported which qualifies as a major hemorrhage (INR 2.8. Hemorrhage occurred ten weeks after inclusion and 12 weeks after start anticoagulant treatment). All other complications were minor hemorrhages. No clear differences between the study groups were found.
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During the trial six patients died. One patient died in the placebo group of myocardial infarction after interruption of treatment because of elective surgery. In the 100 µg group three patients died: one died of malignancy, one died of intracranial hemorrhage one day post-inclusion and one died of unknown cause. In both the 150 µ g and 200 µg group 1 patient died of pneumonia.
Several patients reported having trouble swallowing the study capsules and at least one patient withdrew from the study for this reason. No other side effects of the study capsules were reported.
Discussion
We performed a randomized placebo-controlled trial in two Dutch anticoagulation clinics.
In 400 patients using vitamin K antagonists we examined the effect of supplementation of vitamin K 1 in three different dosages. In comparison to the placebo group the adjusted difference in weighted time in therapeutic range as a measure of stability of the anticoagulant effect was 2.1%, 2.7 % and 0.9 % in the groups using 100, 150 µg and 200 µg vitamin K 1 , respectively. Patients using either 100 µg vitamin K 1 or 150 µg vitamin K 1 had a better chance of reaching a high TTR of at least 85% (odds ratios over 2). There was no difference in the number and severity of complications (both thromboembolic as hemorrhagic) between the four groups.
Our study is the fourth study in its kind. The three previous studies, one pilot study and two trials, showed also a positive effect on stability of anticoagulant therapy. After a pilot study Rombouts et al published the second trial 12 in which 100 patients receiving 100 µ g vitamin K 1 once daily were compared with 100 patients receiving a placebo. All patients used phenprocoumon and were treated with vitamin K antagonists for at least one year before being included in the study. Furthermore, they were not selected on basis of a measure of stability. Only a small adjusted difference in TTR of 3.6% (95%CI: -0.8%-8.0%) was found. were on phenprocoumon. In our trial most patients were using phenprocoumon and a small number of patients used acenocoumarol. These three VKA have a different half-life and previous studies showed a better stability of anticoagulant therapy for the longer acting phenprocoumon in comparison to acenocoumarol. [15] [16] [17] [18] [19] A recent study showed better stability in patients treated with warfarin than in the patients using phenprocoumon. 22 We performed a subgroup analysis in the group of patients treated with acenocoumarol. The difference became more marked between the placebo group and the vitamin K 1 150 µg group, but with wide confidence intervals due to the small number of acenocoumarol users (9.5% difference in TTR (95%CI: -61.8%-80.9%). After pooling all three vitamin K 1 groups for the acenocoumarol users the difference between the pooled vitamin K 1 groups and the placebo group is consistent with the overall outcome of the study (3.5% (95%CI: -15,8%-22.8%)). So, in our study we could not demonstrate a difference on the effectiveness of vitamin K 1 supplementation between phenprocoumon and acenocoumarol. Considering half-life as the discriminating factor it is unlikely that use of warfarin with a half-life between phenprocoumon and acenocoumarol would show a different effect of vitamin K 1 supplementation. Another difference between the various VKA cannot be excluded however in this regard.
Thirdly, the absolute level of anticoagulant control may be of importance. In our study the time in therapeutic range in the placebo group was 84.3% which is far higher than in most other publications, which might be difficult to improve upon by vitamin K 1 supplementation. The total number of complications (47, of which two were thromboembolic, and only one categorized as major hemorrhage) was low in our study population. We did not find a difference in either the number of complications (both thromboembolic and hemorrhagic) or the severity of these complications.
A concern could be that the patients we approached for the trial and were willing to participate, represented a (self-)selection of highly stable patients. We think this to be unlikely since the TTR in our placebo group (84.3%) was similar to all patients treated for mid-to long term indications by both anticoagulation clinics.
We believe the time a person participated in the study should be taken into account in calculating the time in therapeutic range. Therefore we present the primary endpoint as weighted time in range. We cannot exclude the possibility there is for example an unknown patient factor partially responsible for reaching stability which would make an evaluation of unweighted time in range preferable. Therefore we decided to report the outcomes of both the weighted and unweighted analyses.
Although the study was set up as a double-blind trial blinding may not have been entirely complete because of the changes in dose-requirements in patients receiving vitamin K 1 . To minimize this potential unblinding the main researcher did not prescribe dosages of anticoagulant therapy of participating patients.
Unfortunately, we were unable to collect reliable data on patient compliance.
Therefore, we cannot exclude that poor compliance may have resulted in a lower estimate of the effect of vitamin K 1 supplementation. If patients participating in a clinical trial are not motivated to take the vitamin K 1 supplementation it is unlikely that in routine clinical practice patients will do better. Furthermore, it is very unlikely that compliance differed between the study groups. So, we are convinced that compliance did not influence the comparison between the groups nor our final conclusion that low dose vitamin K 1 supplementation does not result in a clinically relevant improvement of time in therapeutic range.
In conclusion we found that daily supplementation with 150 µg vitamin K 1 improved stability of oral anticoagulant therapy with 2.7% TTR. In addition there was a twofold increase in the chance of reaching a TTR of at least 85%. This result is in agreement with a previous study from our institution and we are convinced that the effect,
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The authors reported no potential conflicts of interest. Figure 1 . Flow of patients through the trial. Patients were considered to have dropped out when participating in the study less than four weeks. Out of the 1487 patients who were approached to participate in our study 90 were not included after 400 patients (the number of patients needed) had agreed to participate. 
